vs

Side-by-side financial comparison of DLH Holdings Corp. (DLHC) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $68.9M, roughly 1.1× DLH Holdings Corp.). DLH Holdings Corp. runs the higher net margin — -1.9% vs -121.9%, a 120.0% gap on every dollar of revenue. On growth, Health Catalyst, Inc. posted the faster year-over-year revenue change (-6.2% vs -24.1%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-4.8M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -17.4%).

DLH Holdings Corp. is a U.S.-based provider of technology-enabled healthcare, logistics, engineering, and mission support services primarily serving federal government agencies including the Department of Veterans Affairs, Department of Defense, and Department of Health and Human Services, as well as select state and local government clients across core public service segments.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

DLHC vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.1× larger
HCAT
$74.7M
$68.9M
DLHC
Growing faster (revenue YoY)
HCAT
HCAT
+17.9% gap
HCAT
-6.2%
-24.1%
DLHC
Higher net margin
DLHC
DLHC
120.0% more per $
DLHC
-1.9%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$14.4M more FCF
HCAT
$9.6M
$-4.8M
DLHC
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-17.4%
DLHC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DLHC
DLHC
HCAT
HCAT
Revenue
$68.9M
$74.7M
Net Profit
$-1.3M
$-91.0M
Gross Margin
Operating Margin
2.1%
-115.3%
Net Margin
-1.9%
-121.9%
Revenue YoY
-24.1%
-6.2%
Net Profit YoY
-218.7%
-340.3%
EPS (diluted)
$-0.09
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DLHC
DLHC
HCAT
HCAT
Q4 25
$68.9M
$74.7M
Q3 25
$81.2M
$76.3M
Q2 25
$83.3M
$80.7M
Q1 25
$89.2M
$79.4M
Q4 24
$90.8M
$79.6M
Q3 24
$96.4M
$76.4M
Q2 24
$100.7M
$75.9M
Q1 24
$101.0M
$74.7M
Net Profit
DLHC
DLHC
HCAT
HCAT
Q4 25
$-1.3M
$-91.0M
Q3 25
$-920.0K
$-22.2M
Q2 25
$289.0K
$-41.0M
Q1 25
$878.0K
$-23.7M
Q4 24
$1.1M
$-20.7M
Q3 24
$2.3M
$-14.7M
Q2 24
$1.1M
$-13.5M
Q1 24
$1.8M
$-20.6M
Gross Margin
DLHC
DLHC
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
DLHC
DLHC
HCAT
HCAT
Q4 25
2.1%
-115.3%
Q3 25
2.8%
-22.9%
Q2 25
4.5%
-46.0%
Q1 25
5.7%
-25.4%
Q4 24
6.2%
-22.0%
Q3 24
6.6%
-17.9%
Q2 24
5.7%
-20.8%
Q1 24
5.9%
-30.5%
Net Margin
DLHC
DLHC
HCAT
HCAT
Q4 25
-1.9%
-121.9%
Q3 25
-1.1%
-29.1%
Q2 25
0.3%
-50.8%
Q1 25
1.0%
-29.9%
Q4 24
1.2%
-26.0%
Q3 24
2.4%
-19.3%
Q2 24
1.1%
-17.8%
Q1 24
1.8%
-27.6%
EPS (diluted)
DLHC
DLHC
HCAT
HCAT
Q4 25
$-0.09
$-1.29
Q3 25
$-0.07
$-0.32
Q2 25
$0.02
$-0.59
Q1 25
$0.06
$-0.35
Q4 24
$0.08
$-0.33
Q3 24
$0.16
$-0.24
Q2 24
$0.08
$-0.23
Q1 24
$0.12
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DLHC
DLHC
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$257.0K
$95.7M
Total DebtLower is stronger
$133.5M
$153.3M
Stockholders' EquityBook value
$112.2M
$245.8M
Total Assets
$283.5M
$502.6M
Debt / EquityLower = less leverage
1.19×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DLHC
DLHC
HCAT
HCAT
Q4 25
$257.0K
$95.7M
Q3 25
$125.0K
$91.5M
Q2 25
$194.0K
$97.3M
Q1 25
$196.0K
$342.0M
Q4 24
$451.0K
$392.0M
Q3 24
$342.0K
$387.3M
Q2 24
$423.0K
$308.3M
Q1 24
$238.0K
$327.8M
Total Debt
DLHC
DLHC
HCAT
HCAT
Q4 25
$133.5M
$153.3M
Q3 25
$128.0M
$153.1M
Q2 25
$138.3M
$153.0M
Q1 25
$147.3M
$382.9M
Q4 24
$162.2M
$382.4M
Q3 24
$149.4M
$345.0M
Q2 24
$160.9M
Q1 24
$164.8M
Stockholders' Equity
DLHC
DLHC
HCAT
HCAT
Q4 25
$112.2M
$245.8M
Q3 25
$113.0M
$331.9M
Q2 25
$113.7M
$347.5M
Q1 25
$112.8M
$376.8M
Q4 24
$111.4M
$365.2M
Q3 24
$110.1M
$355.0M
Q2 24
$108.6M
$357.0M
Q1 24
$106.8M
$357.2M
Total Assets
DLHC
DLHC
HCAT
HCAT
Q4 25
$283.5M
$502.6M
Q3 25
$290.7M
$587.1M
Q2 25
$299.3M
$616.2M
Q1 25
$306.6M
$891.5M
Q4 24
$325.0M
$858.9M
Q3 24
$314.4M
$813.0M
Q2 24
$325.0M
$691.7M
Q1 24
$325.9M
$695.1M
Debt / Equity
DLHC
DLHC
HCAT
HCAT
Q4 25
1.19×
0.62×
Q3 25
1.13×
0.46×
Q2 25
1.22×
0.44×
Q1 25
1.31×
1.02×
Q4 24
1.46×
1.05×
Q3 24
1.36×
0.97×
Q2 24
1.48×
Q1 24
1.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DLHC
DLHC
HCAT
HCAT
Operating Cash FlowLast quarter
$-4.8M
$9.9M
Free Cash FlowOCF − Capex
$-4.8M
$9.6M
FCF MarginFCF / Revenue
-7.0%
12.9%
Capex IntensityCapex / Revenue
0.1%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$29.2M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DLHC
DLHC
HCAT
HCAT
Q4 25
$-4.8M
$9.9M
Q3 25
$10.7M
$-464.0K
Q2 25
$9.6M
$-9.0M
Q1 25
$14.5M
$280.0K
Q4 24
$-11.5M
$-3.5M
Q3 24
$12.4M
$6.2M
Q2 24
$4.6M
$1.6M
Q1 24
$5.2M
$10.3M
Free Cash Flow
DLHC
DLHC
HCAT
HCAT
Q4 25
$-4.8M
$9.6M
Q3 25
$10.7M
$-719.0K
Q2 25
$9.4M
$-9.2M
Q1 25
$14.0M
$-390.0K
Q4 24
$-12.1M
$-3.9M
Q3 24
$12.2M
$5.5M
Q2 24
$4.5M
$1.3M
Q1 24
$4.9M
$10.1M
FCF Margin
DLHC
DLHC
HCAT
HCAT
Q4 25
-7.0%
12.9%
Q3 25
13.1%
-0.9%
Q2 25
11.2%
-11.4%
Q1 25
15.6%
-0.5%
Q4 24
-13.3%
-4.9%
Q3 24
12.7%
7.2%
Q2 24
4.4%
1.7%
Q1 24
4.9%
13.5%
Capex Intensity
DLHC
DLHC
HCAT
HCAT
Q4 25
0.1%
0.4%
Q3 25
0.0%
0.3%
Q2 25
0.3%
0.3%
Q1 25
0.6%
0.8%
Q4 24
0.6%
0.5%
Q3 24
0.2%
0.9%
Q2 24
0.2%
0.4%
Q1 24
0.3%
0.3%
Cash Conversion
DLHC
DLHC
HCAT
HCAT
Q4 25
Q3 25
Q2 25
33.12×
Q1 25
16.52×
Q4 24
-10.35×
Q3 24
5.42×
Q2 24
4.06×
Q1 24
2.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DLHC
DLHC

Sales Channel Directly To Consumer$64.5M94%
Sales Channel Through Intermediary$4.4M6%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons